Piramal Pharma's Commitment to Sustainable Growth and Innovation
Piramal Pharma's Focus on Sustainability in 2025
Piramal Pharma Limited (PPL) recently released its fourth annual Sustainability Report for the financial year 2025. This report, themed 'Innovating Responsibly. Growing Sustainably.', sheds light on the company's measurable progress and reinforced commitments across four key strategic pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. PPL stands firm in its purpose of 'Doing Well and Doing Good', promoting science-led innovation and ethical responsibility.
Highlights from the Sustainability Report
The report emphasizes PPL's efforts to implement responsible practices throughout its global operations. This includes enhancing governance, accelerating climate action, advancing diversity and inclusion, and generating social impact through collaborative partnerships. To ensure accountability, the Sustainability Report has been externally assured by a reputable third party.
Business Resilience Updates
PPL has demonstrated significant strides in business resilience, showcasing a board composition of 50% independent directors and elevating women representation to 30%, exceeding statutory requirements. With zero data breaches reported, the company has achieved full compliance with its Code of Conduct training. Furthermore, the company has assessed 26.5% of its critical suppliers against sustainability criteria, aiming to enhance capacity building for an additional 30% by the next fiscal year.
Commitment to Quality & Excellence
PPL's commitment to quality and excellence continues to shine through its accomplishment of 36 successful regulatory inspections, including two by the USFDA, in addition to completing 165 customer audits globally. Emphasizing its digital transformation, PPL has also implemented the Catalyst NxGen (S/4HANA) platform, along with 17 governance dashboards to improve agility and scalability. Notably, the company reported a customer satisfaction score of 85% in CDMO/PPS and 87% in Critical Care/PCC divisions.
Advancements in Responsible Operations
PPL has made significant advancements in responsible operations, particularly in its decarbonization strategies. The company achieved a 6% reduction in Scope 1 & 2 emissions year-over-year and a 7.8% increase in renewable energy use, with bioenergy constituting 20.2% of total energy consumption. Additionally, PPL committed to a zero hazardous waste policy and aims for a 90% recycling rate of non-hazardous waste. Through integrated water stewardship, the company has conserved 210,000 kilolitres of freshwater. Efforts to promote biodiversity have included planting over 2,000 saplings and maintaining a 30% green cover across its facilities.
Fostering Stakeholder Centricity
PPL is deeply invested in promoting diversity, equity, and inclusion (DE&I), revealing that women hold 30% of board positions, while 20% of their global workforce are women. This reflects a 2.7% year-on-year increase in women's representation, with 63.3% of campus hires being women. The company has ensured that 100% of employees are covered under ESG training programs. Safety initiatives have also resulted in a remarkable 45% improvement in the Lost Time Injury Rate, reducing it to just 0.05.
The Vision of Sustainability
Nandini Piramal, Chairperson of Piramal Pharma Limited, expressed, "At Piramal Pharma, sustainability is not just a responsibility — it is a deliberate choice that defines the way we operate and the way we grow. In today's complex environment, shaped by climate change, regulatory shifts, and rising expectations of transparency and ethical conduct, sustainability has become central to long-term value creation. This year, we have advanced our decarbonization journey with measurable reductions in emissions, expanded renewable energy adoption, and intensified efforts on water stewardship and circularity. Equally, our commitment to diversity, equity and inclusion has created a more inclusive workplace culture, while our CSR initiatives have brought meaningful change to over 200 million people across aspirational districts. As we continue to innovate responsibly and grow sustainably, we remain steadfast in our endeavour to create lasting value for our patients, our communities, and for the planet we all share."
Community Engagement and CSR Initiatives
In FY 2025, PPL advanced its Corporate Social Responsibility initiatives across 112 aspirational districts, focusing principally on education, community well-being, and women's empowerment. Investing ?5.34 Crore, the company targeted enhancing school infrastructure, improving teaching capacity, and addressing public health challenges, particularly water safety practices. Employee involvement in volunteer initiatives such as plantation drives and health awareness campaigns further amplified PPL's impact. A notable partnership with the Life Sciences Sector Skill Development Council led to launching a women-led skill development programme near PPL's Digwal plant, showcasing PPL's commitment to aiding underserved communities.
Focused on Global Standards
PPL’s Sustainability Report aligns with the Global Reporting Initiative (GRI) standards, as well as the Sustainability Accounting Standards Board (SASB) and UN Global Compact (UNGC) frameworks. This alignment reflects PPL's commitment to sustainable growth, responsible capital allocation, and meaningful stakeholder engagement.
Frequently Asked Questions
What is Piramal Pharma Limited's main focus in sustainability?
Piramal Pharma Limited is dedicated to creating a blend of responsible innovation and sustainable growth through ethical practices and community engagement.
What progress has PPL made in diversity and inclusion?
PPL has achieved 30% women representation on their board and 20% of their global workforce are women, with a significant annual increase.
How is PPL addressing climate change?
PPL has implemented various decarbonization strategies, including a reduction in emissions and increased renewable energy usage.
What community initiatives has PPL undertaken recently?
PPL has focused on CSR initiatives in 112 aspirational districts, emphasizing education and health, with significant investments in community development.
Where can I find the full sustainability report?
The full sustainability report can be accessed on Piramal Pharma Limited's official website.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.